Carcinoma, Small Cell Lung Clinical Trial
Official title:
A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 2 Study to Investigate the Efficacy and Safety of Atezolizumab With or Without Tiragolumab as Consolidation Therapy in Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed After Chemoradiotherapy
This is a multicenter, double-blind, placebo-controlled, randomized, phase II study to investigate the efficacy and safety of Atezolizumab with or without Tiragolumab as consolidation therapy in participants with limited stage small cell lung cancer who have not progressed during/after chemoradiotherapy.
Participants can receive concurrent or sequential chemoradiotherapy (CRT) as per local standard of care, but they must be randomized within 6 weeks from completion of chemoradiotherapy. Participants should receive 4 cycles of chemotherapy and radiotherapy dose of 56-64 Gy (once daily) before randomization, and those participants who have not progressed during/after CRT will be stratified by response to CRT, radiotherapy timing, and be randomized in a 1:1 ratio to Atezolizumab+Tiragolumab arm or Atezolizumab+placebo arm. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00037713 -
Survival in a Randomized Phase III Trial in Patients With Limited Disease (LD) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 and BCG
|
Phase 3 | |
| Recruiting |
NCT02736916 -
HS-WBRT for Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer
|
N/A | |
| Terminated |
NCT00637624 -
N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing Chemotherapy
|
N/A | |
| Completed |
NCT00308529 -
Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04985357 -
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
|
||
| Active, not recruiting |
NCT01306045 -
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
|
Phase 2 | |
| Terminated |
NCT00435578 -
Safety and Efficacy Study of Glufosfamide in Patients With Recurrent Sensitive Small Cell Lung Carcinoma
|
Phase 2 | |
| Completed |
NCT00294931 -
Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
| Terminated |
NCT00265200 -
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
|
Phase 2 | |
| Completed |
NCT00270166 -
The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy
|
Phase 3 | |
| Completed |
NCT02936323 -
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
|
Phase 1/Phase 2 | |
| Terminated |
NCT03699956 -
RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT00263731 -
Metabolomic Analysis of Lung Cancer
|
||
| Active, not recruiting |
NCT04622228 -
Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT04253145 -
Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05566041 -
A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT03083691 -
BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT03871205 -
Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer
|
Phase 1 |